Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Hold” by Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given a consensus rating of “Hold” by the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $16.57.

YMAB has been the topic of several research reports. HC Wainwright lifted their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Canaccord Genuity Group lifted their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Wedbush restated an “outperform” rating and set a $18.00 price target (up from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Finally, BMO Capital Markets lifted their price objective on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the sale, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 21.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in YMAB. Acadian Asset Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 24.0% in the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after purchasing an additional 157,173 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 17.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after buying an additional 52,610 shares during the last quarter. GSA Capital Partners LLP increased its holdings in shares of Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock worth $748,000 after buying an additional 92,765 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Y-mAbs Therapeutics by 20.1% in the 3rd quarter. Victory Capital Management Inc. now owns 109,500 shares of the company’s stock valued at $597,000 after acquiring an additional 18,320 shares during the last quarter. Finally, Strs Ohio boosted its holdings in Y-mAbs Therapeutics by 20.1% during the 3rd quarter. Strs Ohio now owns 89,000 shares of the company’s stock valued at $485,000 after acquiring an additional 14,900 shares during the period. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ:YMAB opened at $12.87 on Friday. Y-mAbs Therapeutics has a 52-week low of $4.60 and a 52-week high of $20.90. The business’s 50 day simple moving average is $15.61 and its two-hundred day simple moving average is $11.16. The firm has a market cap of $564.65 million, a P/E ratio of -26.27 and a beta of 0.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. The company had revenue of $23.36 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, equities analysts forecast that Y-mAbs Therapeutics will post -0.43 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.